STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study.
23 November 2022, Cambridge, UK. STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announces that the first patient has been dosed with STC-15, the Company’s first-in-class clinical candidate. An orally bioavailable, highly selective METTL3 inhibitor, STC-15 is the […]